Brief: HLS Therapeutics Inc - Reaffirms Peak-Year Sales Forecast For Vascepa
20/07/2020 22:25
July 20 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS INC - REAFFIRMS ITS PEAK-YEAR SALES
FORECAST
FOR VASCEPA
* HLS THERAPEUTICS INC - CADTH RECOMMENDS VASCEPA BE
REIMBURSED
FOR PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE UNDER
CERTAIN CONDITIONS
* HLS THERAPEUTICS INC - PMPRB NOTIFIES HLS THAT VASCEPA'S
INTRODUCTORY PRICE SUBMISSION DID NOT TRIGGER PRICING
INVESTIGATION CRITERIA
Source text for Eikon: ID:nCNWks77ha
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group